Home > About Us > Press Releases > Archives

Archives

• 12-05-07

  ReGen Biologics Introduces New Brand Name and Websites

• 11-21-07

  ReGen Biologics Enters New Markets in Poland and South Africa

• 08-24-07

  ReGen Biologics Receives NSE Letter from FDA, Proceeding with Next Steps to Gain U.S. Market Clearance

• 07-08-07

  ReGen Biologics to Exhibit at 2007 AOSSM Annual Meeting

• 06-25-07

  ReGen Biologics Responds to Request for Additional Information on Pending 510(k)

• 05-24-07

  ReGen Biologics to Launch Lateral CMIâ„¢ at 6th Biennial ISAKOS Congress

• 04-25-07

  ReGen Biologics Participates in 2007 AANA Annual Meeting

• 04-04-07

  ReGen Biologics Closes $2.7 Million Private Placement

• 03-05-07

  ReGen Biologics Closes Additional $3 Million Private Placement

• 02-25-07

  ReGen Biologics Data Presented in San Diego

• 02-05-07

  ReGen Biologics to Present at First Albany’s Second Annual Orthopedics Conference on February 13, 2007

• 02-04-07

  ReGen Biologics Participates in 2007 AAOS Annual Meeting

• 12-03-06

  ReGen Biologics Completes Approximately $7 Million Private Placement

• 11-12-06

  ReGen Biologics Announces Results of FDA Appeal

• 11-06-06

  ReGen Biologics Announces New CMI Clinical Results

• 09-06-06

  ReGen Biologics Provides Update on 510(k) Submission

• 06-19-06

  ReGen Biologics Tissue Growth Data Presented

• 05-30-06

  Regen Biologics CMIâ„¢ Topic of Symposium

• 05-15-06

  ReGen Biologics Hosts Annual Shareholder Meeting

• 05-07-06

  ReGen Biologics Meniscus Data To Be Presented

• 05-02-06

  Recent Article Validates Tools Used by ReGen Biologics to Measure Meniscus Performance

• 04-30-06

  ReGen Biologics Reports First Bilateral CMIâ„¢ Procedure

• 04-27-06

  ReGen Biologics Provides Update on 510(K) Regulatory Submission

• 02-26-06

  CMIâ„¢ Labeling Expanded in Europe to Include Lateral Use

• 01-29-06

  ReGen Biologics Meniscus Data Featured in Scientific Meetings

• 01-03-06

  ReGen Biologics Announces 510(k) Regulatory Submission in the U.S.

• 11-20-05

  ReGen Biologics Completes Distribution Coverage in Spain with Exclusive Agreement

• 11-15-05

  Regen Biologics Signs Exclusive Distribution Agreement for Spain

• 11-13-05

  International Symposium Features Latest CMIâ„¢ Data

• 10-30-05

  ReGen Biologics Signs Exclusive Distribution Agreement for Italy

• 08-29-05

  ReGen Biologics Launches European Website

• 08-22-05

  FDA Follows-up on Form 483 Notice of Inspectional Observations with Warning Letter

• 07-14-05

  ReGen Biologics Completes $11.8 Million Private Placement

• 05-25-05

  ReGen Biologics AG to Host June 6, 2005 Evening Event at EFORT Congress in Lisbon for Surgeons Interested in ReGen® CMI

• 05-24-05

  ReGen Biologics Surgeons Successfully Complete Lateral CMIâ„¢Surgeries

• 05-24-05

  ReGen Biologics To Present at the Pacific Growth Equities Life Science Conference in San Francisco on June 6, 2005

• 05-16-05

  ReGen Biologics Announces Publication of Five Year Data from CMI Feasibility Study in Arthroscopy

• 03-17-05

  ReGen Biologics Reports Select Operating Results for 2004

• 03-06-05

  ReGen Regains Exclusive Worldwide Distribution Rights for its CMI

• 10-06-04

  ReGen Biologics to Present at the HealthPoint Capital New York Biomaterials Summit

• 07-25-04

  ReGen Biologics Begins Modular FDA Pre-Market Approval Submission for CMI Product

• 06-09-04

  William R. Timken, Former Vice Chairman of Hambrecht & Quist, Named to ReGen Biologics Board of Directors

• 04-20-04

  ReGen Biologics Completes Private Placement of Common Stock for Gross Proceeds of Approximately $10.3 Million

• 02-26-04

  ReGen Biologics Continues Advance Towards FDA Submission with the Selection of Key FDA Consulting Firm

• 11-30-03

  ReGen Biologics to Present at Harris Nesbitt Gerard Focus on Healthcare Conference December 11 in New York City

• 10-27-03

  ReGen Biologics Retains Cameron Associates as Investor Relations Advisor

• 10-15-03

  ReGen Biologics To Present At Rodman & Renshaw Techvest Healthcare Conference

• 09-30-03

  ReGen Biologics Finalizes Private Placement Totaling $10 Million

• 08-22-03

  ReGen Biologics Completes Private Placement

• 05-18-03

  ReGen Biologics Appoints Abhi Acharya, Ph.D. to Board of Directors

• 03-18-03

  ReGen Biologics Launches New Website

• 01-05-03

  ReGen Biologics Announces 2002 Accomplishments

• 12-01-02

  ReGen Biologics Filed U.S. Patent Application for Membrane Enforced Implant

• 11-21-02

  ReGen Biologics CEO Interview at Ceocast.com

• 11-19-02

  ReGen Announces Completion of CMI Clinical Trial Surgeries

• 11-18-02

  Aros Corporation Announces Name and Ticker Change

• 10-21-02

  German Magazine, Stern, Interviews ReGen Biologics’ Director, Dr. Richard Steadman and Highlights ReGen’s Groundbreaking Meniscal Repair Procedure

• 09-29-02

  ReGen Obtains Approval in Australia

• 09-25-02

  ReGen Biologics Announces the Completion of U.S. Clinical Trial Enrollments

• 09-22-02

  Aros To Postpone Annual Meeting of Stockholders

• 07-18-02

  ReGen CMI Featured At 3rd International Heidelberg Orthopedic Symposium

• 06-24-02

  Aros Completes Acquisition of ReGen Biologics

• 07-04-00

  ReGen Biologics CMI Recognized With GOTS-Beiersdorf Orthopaedic Research Award

• 05-10-00

  ReGen Biologics Receives Financing From Sulzer Medica

• 04-16-00

  ReGen Biologics Announces Licensing Agreement For The SharpShooter® Tissue Repair System for Meniscus Repair

• 04-04-00

  ReGen Biologics Commences European Market Launch of CMI Through Sulzer Medica

• 02-21-00

  ReGen Biologics Receives CE Marking for CMI